NCT04754334View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

ORMD-0801

Oral Insulin

OTHER

Placebo

Fish Oil

Trial Locations (1)

33124

Research Institute of South Florida, Inc. (PHARMASEEK), Coral Gables

Sponsors

Collaborators (1)

Integrium
All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Oramed, Ltd.

INDUSTRY

NCT04754334 - A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter